Novartis AG, Shire Weighing $1.3 Billion Offer For ThromboGenics NV

Published: Apr 15, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis AG (NOVN) and Shire Plc (SHP) are among drugmakers weighing offers for Belgian eye-medicine company ThromboGenics NV (THR), people familiar with the matter said. Novartis, which is based in Basel, Switzerland, is considered the most likely buyer because it already has a partnership to market ThromboGenics’s Jetrea eye medicine outside of the U.S., the people said, asking not to be identified because the process is private. The sale may value the company at as much as $1.3 billion, one of the people said.

Help employers find you! Check out all the jobs and post your resume.

Back to news